Morgan Stanley on United Therapeutics Corp. (UTHR): project Tyvaso '2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn'

Morgan Stanley analyst Terence Flynn reiterated an Equalweight rating and $471.00 price target on United Therapeutics Corp. (NASDAQ: UTHR)

The analyst commented, "UTHR reported that Tyvaso met the primary endpoint in a second Ph3 idiopathic pulmonary fibrosis (IPF) trial, TETON-1 demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo of 130.1mL (p<0.0001) from baseline to week 52 (LINK). The magnitude of improvement is above that observed in the first Ph3 trial, TETON-2 (LINK). We expect UTHR shares to trade up as a result... Next steps: Additional TETON-1 study results and data from the integrated analyses of TETON-1 and TETON-2 will be presented at the ATS Annual Meeting in May 2026. UTHR plans to seek priority review of a supplemental New Drug Application, to be submitted to FDA by the end of this summer, to add IPF to Tyvaso's label. We project Tyvaso 2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn (75% POS). We see upside to our estimates as a result of these data."

For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $522.83 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• JPMorgan Downgrades KFin Technologies Ltd (KFINTECH:IN) to Neutral
• Barclays Upgrades Telia Co AB (TELIA:SS) (TLSNF) to Equalweight